Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $100.85 USD
Change Today -1.88 / -1.83%
Volume 136.1K
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

bio-techne corp (TECH) Snapshot

Open
$103.00
Previous Close
$102.73
Day High
$103.00
Day Low
$100.73
52 Week High
04/24/15 - $103.00
52 Week Low
04/28/14 - $83.83
Market Cap
3.7B
Average Volume 10 Days
215.3K
EPS TTM
$3.27
Shares Outstanding
37.1M
EX-Date
02/11/15
P/E TM
30.9x
Dividend
$1.28
Dividend Yield
1.25%
Current Stock Chart for BIO-TECHNE CORP (TECH)

Related News

No related news articles were found.

bio-techne corp (TECH) Related Businessweek News

No Related Businessweek News Found

bio-techne corp (TECH) Details

Bio-Techne Corporation develops, manufactures, and sells biotechnology products and clinical diagnostic controls worldwide. It operates in two segments, Biotechnology and Clinical Controls. The Biotechnology segment provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising quantikine kits used by researchers to quantify the level of a specific protein in biological fluids, such as serum, plasma, or urine; and clinical diagnostic immunoassay kits consisting of erythropoietin, transferrin receptor, and Beta2-microglobulin immunoassays for use as in vitro diagnostic devices. This segment also offers flow cytometry products, such as fluorochrome labeled antibodies and kits for use in determining the immuno-phenotypic properties of cells from various tissues; and natural and synthetic chemical compounds for use by investigators as agonists, antagonists, and/or inhibitors of various biological functions. The Clinical Controls segment provides a range of hematology controls and calibrators for impedance and laser type cell counters; and hematology control products for use as proficiency testing tools by laboratory certifying authorities. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

967 Employees
Last Reported Date: 08/29/14
Founded in 1976

bio-techne corp (TECH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $586.4K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $79.4K
Senior Vice President of Clinical Controls
Total Annual Compensation: $225.0K
Chief Technical Officer
Total Annual Compensation: $223.1K
Vice President of Operations and Product Deve...
Total Annual Compensation: $276.5K
Compensation as of Fiscal Year 2014.

bio-techne corp (TECH) Key Developments

Bio-Techne Corporation Announces Executive Changes

On March 17, 2015, Bio-Techne Corporation appointed N. David Eansor, previously serving as senior vice president, Novus Biologicals, to the position of senior vice president, Biotech Division, effective April 1, 2015. Kevin Reagan, who had held the position as senior vice president, Biotech Division, will assume the role as vice president, operations and product development for the Biotech Division, reporting to Mr. Eansor. There will be no changes to Mr. Reagan's employment agreement or compensation as a result of this new position and responsibilities.

Bio-Techne Corp. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended December 31, 2014

Bio-Techne Corp. announced consolidated unaudited earnings results for the second quarter and six months ended December 31, 2014. For the quarter, the company reported net sales of $111,948,000 against $84,017,000 a year ago. Operating income was $34,580,000 against $35,744,000 a year ago. Earnings before income taxes were $42,563,000 against $36,218,000 a year ago. Net earnings were $33,209,000 or $0.89 per diluted share against $25,055,000 or $0.68 per diluted share a year ago. Net earnings - adjusted was $30,345,000 or $0.82 per diluted share against $27,590,000 or $0.75 per diluted share a year ago. Cash generated from operations for the second quarter of fiscal 2015 was $35.7 million.  Capital expenditures for the second quarter of fiscal 2015 were $3.1 million. For the six months, the company reported net sales of $220,425,000 against $169,685,000 a year ago. Operating income was $69,796,000 against $75,135,000 a year ago. Earnings before income taxes were $77,161,000 against $75,872,000 a year ago.Net earnings was $57,116,000 against or $1.54 per basic and diluted share against $52,483,000 or $1.42 per basic and diluted share a year ago. Net earnings - adjusted was $62,081,000 or $1.67 per diluted share against $58,066,000 or $1.57 per diluted share a year ago.

Bio-Techne Corp. Declares Dividend for the Quarter Ended December 31, 2014, Payable on February 27, 2015

Bio-Techne Corp. announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2014. The quarterly dividend will be payable on February 27, 2015 to all common shareholders of record on February 13, 2015. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TECH:US $100.85 USD -1.88

TECH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abcam PLC 524.00 GBp -1.00
Enzo Biochem Inc $3.01 USD -0.02
Sigma-Aldrich Corp $139.00 USD +0.03
Thermo Fisher Scientific Inc $130.02 USD +0.47
View Industry Companies
 

Industry Analysis

TECH

Industry Average

Valuation TECH Industry Range
Price/Earnings 32.4x
Price/Sales 9.2x
Price/Book 4.6x
Price/Cash Flow 32.4x
TEV/Sales 8.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIO-TECHNE CORP, please visit www.techne-corp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.